Oragenics, Inc. (ORAGENICS INC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 1, 2015, by Oragenics, Inc., a Florida corporation. The report details a specific corporate event occurring on December 1, 2015, regarding the conversion of a debt instrument into equity.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or overall debt levels. The primary financial event reported is:
- Transaction: Conversion of a Convertible Promissory Note into common stock.
- Shares Issued: 3,381,004 shares of Company common stock.
- Counterparty: Intrexon Corporation.
- Conversion Price: $1.50 per share (based on the NYSE MKT closing price on the last trading day prior to conversion).
- Total Value Implied: Approximately $5,071,506 (3,381,004 shares x $1.50).
- Underlying Debt: The Note was originally issued on June 9, 2015, as payment for a technology access fee under an Exclusive Channel Collaboration Agreement.
Material Changes Versus Prior Period
The filing does not provide comparative financial data or year-over-year changes. The material change reported is the reduction of the Company's debt obligations to Intrexon and the corresponding increase in outstanding common stock shares effective December 1, 2015.
Guidance, Outlook, and Risks
Management Commentary: The issuance was made to satisfy obligations under the Note. The Company relied on exemptions from federal registration under Section 4(2) and Regulation D (Rule 506) of the Securities Act of 1933, citing that Intrexon is an accredited investor and no public offering occurred.
Risks and Contingencies: The filing notes the reliance on specific securities law exemptions. The underlying agreement relates to the development and commercialization of products, including AG013 for oral mucositis and trefoil factor delivery, excluding anti-cancer effectors.
Key Facts for Investor Verification
- Verify the impact of the 3,381,004 new shares on total outstanding share count and potential dilution.
- Confirm the full terms of the Exclusive Channel Collaboration Agreement and the Convertible Promissory Note referenced in Exhibits 10.1, 10.2, and 10.3.
- Assess the status of the AG013 development program and the commercialization timeline with Intrexon.
- Review the Company's cash position post-conversion, as the debt obligation was settled via equity rather than cash.